Skip to main content
Erschienen in: Child's Nervous System 9/2021

Open Access 08.02.2021 | Case Report

Pseudotumor cerebri syndrome in a child with Alagille syndrome: intracranial pressure dynamics and treatment outcome after ventriculoperitoneal shunting

verfasst von: Manolis Polemikos, Elvis J. Hermann, Hans E. Heissler, Hans Hartmann, Joachim K. Krauss

Erschienen in: Child's Nervous System | Ausgabe 9/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Abstract

Alagille syndrome (AS) is a rare multisystem disease of the liver, heart, eyes, face, skeleton, kidneys, and vascular system. The occurrence of pseudotumor cerebri syndrome (PTCS) in patients with AS has been reported only exceptionally. Owning to its rarity and a mostly atypical presentation, the diagnosis and natural history of affected patients remain uncertain. We report an atypical case of PTCS in a 4-year-old boy with a known history of AS who presented with bilateral papilledema (PE) on a routine ophthalmological examination. Visual findings deteriorated after treatment with acetazolamide. Continuous intracranial pressure (ICP) monitoring was then utilized to investigate ICP dynamics. Successful treatment with resolution of PE was achieved after ventriculoperitoneal shunting but relapsed due to growth-related dislocation of the ventricular catheter. This report brings new insights into the ICP dynamics and the resulting treatment in this possibly underdiagnosed subgroup of PTCS patients. It also demonstrates that ventriculoperitoneal shunting can provide long-term improvement of symptoms for more than 10 years.
Hinweise

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
AS
Alagille syndrome
CSF
Cerebrospinal fluid
ICP
Intracranial pressure
IIH
Idiopathic intracranial hypertension
PE
Papilledema
PTCS
Pseudotumor cerebri syndrome
Alagille syndrome (AS) or arteriohepatic dysplasia is a rare (1:30,000) autosomal-dominant inherited multisystem disorder [15]. It primarily affects the liver, heart, eyes, face, skeleton, kidneys, and vascular system, whereas its expressivity (phenotypic severity) is highly variable, ranging from no apparent clinical involvement to severe disease that requires liver transplantation [1, 8, 16, 19].
Pseudotumor cerebri syndrome (PTCS) is a disorder characterized by elevated intracranial pressure (ICP) with normal cerebrospinal fluid (CSF) composition in the absence of hydrocephalus, mass lesions, or structural abnormalities. Common presenting signs and symptoms of elevated ICP include papilledema (PE), visual disturbances, and headache. PTCS can be differentiated in a primary form of unknown etiology, which is also termed idiopathic intracranial hypertension (IIH), and a secondary form in which intracranial hypertension results from a medical condition or an exogenous agent [2, 11, 12, 24].
The occurrence of PTCS in AS is exceedingly rare [9, 10, 20, 21]. Thus far ICP monitoring has not been reported in this subgroup of PTCS. Furthermore, owing to their rarity, the natural history and treatment of PTCS in AS patients remain unclear. Here, we present the clinical findings, ICP dynamics, and treatment outcome in a 4-yead-old boy with AS and associated PTCS. Furthermore, previous reports are being reviewed and the possible pathophysiology is discussed.

Case report

History and examination
This 4-year-old boy had a known history of AS. He was born full term at 40 weeks’ gestation by Cesarean section secondary to cephalopelvic disproportion following an uncomplicated pregnancy. At 28 days of age, he underwent a Kasai procedure for biliary atresia. Due to progression of his liver disease, a liver transplantation was performed at 11 months of age after AS had been diagnosed. At 4 years of age, bilateral PE was detected in a routine ophthalmological examination.
He was then referred to the neuropediatric department for further evaluation. On clinical examination, he had a normal blood pressure, his weight was 16.5 kg, and his height 96 cm. Neuropediatric examination was normal. Laboratory studies including renal and liver function parameters were normal. An echocardiogram revealed no cardiovascular abnormalities.
Medication consisted of immunosuppressive therapy with ciclosporine (70 mg/day), mycophenolate mofetil (400 mg/day), and prednisolone (1 mg/day). The cyclosporine level was within normal range.
An MRI scan was performed in which hydrocephalus, mass effect, or structural lesion was ruled out. Subsequently, a lumbar puncture in propofol sedation was achieved revealing a recumbent opening pressure of 48 cm H2O. Examination of the CSF including bacteriological and viral panels showed no abnormalities. Consequently acetazolamide treatment was initiated at a 2 × 125 mg dosage. After 6 weeks, the PE persisted and also deterioration of the visual acuity was documented. In a repeat LP, the opening pressure was still elevated at 34 cm H2O. Repeat neuroimaging assessment remained unremarkable.
Given the progressive visual loss and the PE being refractory to medical treatment, the patient was referred to the Department of Neurosurgery for further evaluation and measurement of ICP dynamics.
Intracranial pressure monitoring
An epidural sensor (Neurodur®, Raumedic, Münchberg, Germany) was implanted over the right frontal area via a precoronal burrhole, and the ICP was monitored for 2 days. ICP monitoring demonstrated massive dynamic ICP changes over time with markedly increased ICP values most of the time (Fig. 1). The decomposition of pressure traces revealed pressure waves with amplitudes reaching values up to 60 mmHg for several minutes. B-waves dominated ICP dynamics superposing the slower ICP fluctuations in time. Additionally, a relatively high number of A-wave pressure transients were scattered in the traces. The majority of ICP values were measured to be within the range of 15 to 70 mmHg (83%).
Shunt surgery and postoperative course
Subsequent to ICP monitoring, a ventriculoperitoneal shunt was implanted using an optic-guided neuronavigation system (Medtronic, Minneapolis, MN, USA). A proGAV® valve with an integrated shuntassistant® (Aesculap-Miethke, Tuttlingen, Germany) was implanted at an opening pressure of 10 cm H20 [25]. The CT scan on the first postoperative day demonstrated an accurately placed ventricular catheter, and the patient was discharged on the seventh postoperative day.
One month after discharge, PE had completely resolved. Further follow-ups were unremarkable until a growth-related dislocation of the ventricular catheter was noted 3.5 years after the shunting procedure. An ophthalmological examination showed relapse of bilateral PE. The ventricular catheter was revised and the immediate postoperative course was uneventful. One month following discharge, the shunt system was explanted due to an infection with Staphylococcus aureus and an external ventricular drain was placed. Antibiotics were administrated intravenously for 3 weeks. When serial CSF bacterial cultures were negative, a new ventriculoperitoneal shunt was inserted guided by electromagnetic neuronavigation (AxiEM) [14]. The valve was set at an opening pressure of 6 cm H2O. Postoperative CT confirmed an accurately placed ventricular catheter. At long-term follow-up (12 years), there was no recurrence and both ophthalmological and neurological findings were unremarkable. The opening pressure has not been adjusted during the follow-up period.

Discussion

The natural course of AS is associated with high morbidity and mortality if not being diagnosed timely and treated appropriately [16]. AS is associated with a plethora of ophthalmological abnormalities, predominately posterior embryotoxon, optic disc drusen, angulated retinal vessels, and pigmentary retinopathy [17]. In the majority of patients, normal vision can be secured [18]. PE is the most common sign of elevated ICP in PCTS, which can lead to progressive visual loss, when left untreated [26]. Although PE is not associated commonly with AS, concomitant congenital optic disc anomalies can be misinterpreted as PE and consequently result in misdiagnosis and unnecessary treatment [5, 17].
The typical patient with primary PTCS or IIH is a young obese woman in childbearing age [12, 29]. Establishing the diagnosis of primary PCTS in a typical patient is mostly a straightforward process based on the 2013 revision of the Friedman & Jacobson criteria [12]. These require that in the presence of PE the opening pressure measured at lumbar puncture is elevated, the CSF composition is normal, there is no evidence of neurological deficits except for cranial nerve abnormalities, and there are no pathological findings in MRI with and without gadolinium [5, 11, 12]. In contrast, the clinical profile of pediatric PCTS differs widely. Pediatric patients frequently remain asymptomatic but PE is incidentally diagnosed in up to 30% during a routine eye examination [4, 13, 27, 28]. Correct diagnosis in pediatric patients is challenging. Opposite to adults, in children gender distribution is equal and weight is not a contributing factor for disease development. It has been estimated that up to 30% of children with PTCS and a normal body weight harbor a secondary etiology; therefore, appropriate identification of causative factors and conditions is essential prior further treatment [3, 27].
The optimal treatment of PTCS in children remains debatable. The main stay of PTCS medical treatment in adults is acetazolamide. Surgical treatment (CSF shunting procedures, optic nerve sheath fenestration, and venous stenting) is indicated when visual loss is progressive and/or symptoms are intractable despite maximal medical management [14, 23, 28].
Although continuous ICP-monitoring is not routinely performed for diagnosing PTCS, it has been shown that its application is a helpful adjunct especially in atypical cases and when surgical treatment is considered [23, 30]. Especially in pediatric patients, it can provide an accurate measurement of ICP, which is commonly overestimated through a lumbar puncture [6]. An increased baseline ICP, large ICP fluctuations, and the presence of ICP-oscillations (A- and B-waves) during recordings further can confirm the diagnosis [23, 30].
The occurrence of PCTS in patients with AS is exceedingly rare with only few patients having been reported thus far (Table 1). Identifying true risk factors is important for establishing the diagnosis of PCTS and also for understanding the pathophysiology of the disorder [7].
Table 1
Summary of patients with PTCS and Alagille syndrome
Authors and year
Age at presentation/sex
Clinical presentation
Opening pressure/cm H20
Time between LT and PTCS development/immunosuppression
Vitamin A level/supplementation
Therapy
Outcome
Follow-up duration (years)
Emerick et al., 2005
3 yrs./M
symptomatic, PE
Raised/24
Not transplanted
ns/ns
Acetazolamide and dexamethasone
Full recovery
ns
Narula et al., 2006
6 yrs./NS
symptomatic, PE
Raised/ns
4 yrs./tacrolimus and steroids
Normal/no
Acetazolamide and prednisolone, LPS after 15 mo
PE resolved, normal vision
ns
25 mo/NS
asymptomatic PE
Raised/ns
16 mo/tacrolimus (changed from cyclosporine due to early rejection)
Elevated before PTCS development, normal after PTCS development/ns
Furosemide
Normal CSF pressure and vision
ns
20 mo/NS
Asymptomatic PE
Raised/ns
Not transplanted
Normal/no
Repeated LP (3×)
Normal development and vision
ns
Ertekin et al., 2010
5 yrs./M
Symptomatic
Raised/29
Not transplanted
Elevated/yes, less than recommended levels
Repeated LPs, acetazolamide
Symptom free
ns
Mouzaki et al., 2010
25 mo/F
Asymptomatic PE
Raised/37
Not transplanted
Elevated/no
Acetazolamide
Improvement of PE
0.5
13 mo/M
Asymptomatic PE
Raised/35
Not transplanted
Elevated/no
Acetazolamide
Improvement of PE
ns
Polemikos et al., 2020
4 yrs./M
Asymptomatic PE
Raised/48
3 yrs./cyclosporine, steroids, mucophenolat mofetil
Normal/no
Acetazolamide, VPS after 6 weeks
Complete resolution of PE
12
F, female; M, male; LP, lumbar puncture; LPS, lumboperitoneal shunt; LT, liver transplantation; ns, not stated; PE, papilledema; VPS, ventriculoperitoneal shunt; PTCS, pseudotumor cerebri syndrome
Both hypervitaminosis and hypovitaminosis A are risk factors for PCTS, and may be relevant in AS since most patients have a fat-soluble vitamin deficiency of variable degree which necessitates supplementation [15]. Previous reports have considered elevated vitamin A levels as causative agent of PCTS in AS, two of them in the absence of vitamin A supplementation [21] and one while on receiving vitamin A and D in less than recommended levels [10].
From a pathophysiological point of view, it has been hypothesized that an increased production of CSF or an increased resistance to CSF outflow is the underlying mechanisms for PTCS, whereas most evidence supports the latter, possibly due to a field effect involving epithelial membranes [20]. Sheldon et al. proposed a neuroendocrine pathomechanism for pediatric PTCS. They hypothesized that in PTCS hormonal and metabolic factors regulate CSF production and CSF absorption ultimately leading to elevated ICP [24]. Furthermore, genetic or epigenetic factors appear to be relevant for developing PCTS, based on previously reported familial cases of PTCS [23].
In 89% of cases, AS is caused by mutations/deletions in the Notch signaling pathway ligand gene, JAGGED1, or the gene for its receptor, NOTCH2 [16]. The Notch signaling pathway has an important role in vascular development. Disruption of this pathway results in abnormal vascular development and signaling, which may also contribute to the development of IIH [15, 22]. Mouzaki et al. speculated that abnormalities in the microvasculature of the choroid plexus in AS patients could lead to abnormal CSF production or absorption, which in turn would cause intracranial hypertension [21].
The occurrence of PTCS in AS patients after liver transplantation has been previously described in 2 cases by Narula et al. [22]. While these patients were on tacrolimus, our patient was receiving cyclosporine, which has been related to the development raised ICP after renal, bone marrow, and heart transplantation. Nevertheless, based on the occurrence of intracranial hypertension in AS patients without liver transplant, it appears unlikely that the immunosuppressive medication solely resulted in PCTS, although it could have been a contributing factor [22].
Due to its rarity, knowledge about treatment of PTCS in AS remains very limited. This is reflected by the few previously reported cases as outlined in Table 1. While medical treatment with acetazolamide, furosemide, and steroids was effective, there is only very little information on long-term efficacy. We here show that ventriculoperitoneal shunting may provide long-term relief and prevent recurrent PE. Relapse of PE due to growth-related dislocation of the ventricular catheter reinforces the need of ophthalmological and radiological follow-up examinations.
PTCS in AS is likely to be underdiagnosed because ophthalmological examinations are not performed routinely after initial diagnostic workup and due to the fact that the majority of patients remain asymptomatic [22].

Conclusions

Our report emphasizes the need for careful evaluation of PCTS in pediatric AS. Through the utility of continuous ICP monitoring, we offer new insights regarding ICP dynamics of this population. We also demonstrate that CSF shunting may provide reliable relief of symptoms on long-term follow-up. Our findings along with other reported cases suggest that a genetic predisposition makes AS patients susceptible for developing PCTS, whereas associated medical conditions and exogenous factors can trigger or exacerbate intracranial hypertension. The differentiation of PTCS in AS as primary or secondary PCTS is a subject deserving further discussion with findings thus far being supportive for the first.

Declarations

Conflict of interest

The authors declare no competing interests.

Code availability

Not applicable.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Neurologie & Psychiatrie

Kombi-Abonnement

Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.

e.Med Neurologie

Kombi-Abonnement

Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.

Weitere Produktempfehlungen anzeigen
Literatur
1.
Zurück zum Zitat Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP (1987) Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 110:195–200CrossRef Alagille D, Estrada A, Hadchouel M, Gautier M, Odièvre M, Dommergues JP (1987) Syndromic paucity of interlobular bile ducts (Alagille syndrome or arteriohepatic dysplasia): review of 80 cases. J Pediatr 110:195–200CrossRef
2.
Zurück zum Zitat Ball AK, Clarke CE (2006) Idiopathic intracranial hypertension. Lancet Neurol 5:433–442CrossRef Ball AK, Clarke CE (2006) Idiopathic intracranial hypertension. Lancet Neurol 5:433–442CrossRef
3.
Zurück zum Zitat Barmherzig R, Szperka CL (2019) Pseudotumor cerebri syndrome in children. Curr Pain Headache Rep 23:58CrossRef Barmherzig R, Szperka CL (2019) Pseudotumor cerebri syndrome in children. Curr Pain Headache Rep 23:58CrossRef
4.
Zurück zum Zitat Bassan H, Berkner L, Stolovitch C, Kesler A (2008) Asymptomatic idiopathic intracranial hypertension in children. Acta Neurol Scand 118:251–255CrossRef Bassan H, Berkner L, Stolovitch C, Kesler A (2008) Asymptomatic idiopathic intracranial hypertension in children. Acta Neurol Scand 118:251–255CrossRef
5.
Zurück zum Zitat Bridges KJ, Raslan AM (2018) Utility of intracranial pressure monitoring for diagnosis of idiopathic intracranial hypertension in the absence of papilledema. World Neurosurg 111:e221–e227CrossRef Bridges KJ, Raslan AM (2018) Utility of intracranial pressure monitoring for diagnosis of idiopathic intracranial hypertension in the absence of papilledema. World Neurosurg 111:e221–e227CrossRef
6.
Zurück zum Zitat Cartwright C, Igbaseimokumo U (2015) Lumbar puncture opening pressure is not a reliable measure of intracranial pressure in children. J Child Neurol 30:170–173CrossRef Cartwright C, Igbaseimokumo U (2015) Lumbar puncture opening pressure is not a reliable measure of intracranial pressure in children. J Child Neurol 30:170–173CrossRef
7.
Zurück zum Zitat Chen J, Wall M (2014) Epidemiology and risk factors for idiopathic intracranial hypertension. Int Ophthalmol Clin 54:1–11CrossRef Chen J, Wall M (2014) Epidemiology and risk factors for idiopathic intracranial hypertension. Int Ophthalmol Clin 54:1–11CrossRef
8.
Zurück zum Zitat Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA (1999) Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 29:822–829CrossRef Emerick KM, Rand EB, Goldmuntz E, Krantz ID, Spinner NB, Piccoli DA (1999) Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 29:822–829CrossRef
9.
Zurück zum Zitat Emerick KM, Krantz ID, Kamath BM, Darling C, Burrowes DM, Spinner NB, Whitington PF, Piccoli DA (2005) Intracranial vascular abnormalities in patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 41:99–107CrossRef Emerick KM, Krantz ID, Kamath BM, Darling C, Burrowes DM, Spinner NB, Whitington PF, Piccoli DA (2005) Intracranial vascular abnormalities in patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 41:99–107CrossRef
10.
Zurück zum Zitat Ertekin V, Selimoğlu MA, Tan H (2010) Pseudotumor cerebri due to hypervitaminosis a or hypervitaminosis D or both in Alagille syndrome. Headache 50:152–153CrossRef Ertekin V, Selimoğlu MA, Tan H (2010) Pseudotumor cerebri due to hypervitaminosis a or hypervitaminosis D or both in Alagille syndrome. Headache 50:152–153CrossRef
11.
Zurück zum Zitat Friedman DI, Jacobson DM (2002) Diagnostic criteria for idiopathic intracranial hypertension. Neurology 59:1492–1495CrossRef Friedman DI, Jacobson DM (2002) Diagnostic criteria for idiopathic intracranial hypertension. Neurology 59:1492–1495CrossRef
12.
Zurück zum Zitat Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81:1159–1165CrossRef Friedman DI, Liu GT, Digre KB (2013) Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology 81:1159–1165CrossRef
13.
Zurück zum Zitat Galvin JA, Van Stavern GP (2004) Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 223:157–160CrossRef Galvin JA, Van Stavern GP (2004) Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 223:157–160CrossRef
14.
Zurück zum Zitat Hermann EJ, Polemikos M, Heissler HE, Krauss JK (2017) Shunt surgery in idiopathic intracranial hypertension aided by electromagnetic navigation. Stereotact Funct Neurosurg 95:26–33CrossRef Hermann EJ, Polemikos M, Heissler HE, Krauss JK (2017) Shunt surgery in idiopathic intracranial hypertension aided by electromagnetic navigation. Stereotact Funct Neurosurg 95:26–33CrossRef
15.
Zurück zum Zitat Kamath BM, Loomes KM, Piccoli DA (2010) Medical management of Alagille syndrome. J Pediatr Gastroenterol Nutr 50:580–586CrossRef Kamath BM, Loomes KM, Piccoli DA (2010) Medical management of Alagille syndrome. J Pediatr Gastroenterol Nutr 50:580–586CrossRef
16.
Zurück zum Zitat Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N (2018) Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr 67:148–156CrossRef Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N (2018) Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr 67:148–156CrossRef
17.
Zurück zum Zitat Kim BJ, Fulton AB (2007) The genetics and ocular findings of Alagille syndrome. Semin Ophthalmol 22:205–210CrossRef Kim BJ, Fulton AB (2007) The genetics and ocular findings of Alagille syndrome. Semin Ophthalmol 22:205–210CrossRef
18.
Zurück zum Zitat Krantz ID, Piccoli DA, Spinner NB (1997) Alagille syndrome. J Med Genet 34:152–157CrossRef Krantz ID, Piccoli DA, Spinner NB (1997) Alagille syndrome. J Med Genet 34:152–157CrossRef
19.
Zurück zum Zitat McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB (2006) NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the NOTCH signaling pathway. Am J Hum Genet 79:169–173CrossRef McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, Spinner NB (2006) NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the NOTCH signaling pathway. Am J Hum Genet 79:169–173CrossRef
20.
Zurück zum Zitat McGeeney BE, Friedman DI (2014) Pseudotumor cerebri pathophysiology. Headache 54:445–458CrossRef McGeeney BE, Friedman DI (2014) Pseudotumor cerebri pathophysiology. Headache 54:445–458CrossRef
21.
Zurück zum Zitat Mouzaki M, Nichter C, Qureshi M, Rountree B, Furuya KN (2010) Idiopathic intracranial hypertension in two patients with Alagille syndrome. J Child Neurol 25:1006–1008CrossRef Mouzaki M, Nichter C, Qureshi M, Rountree B, Furuya KN (2010) Idiopathic intracranial hypertension in two patients with Alagille syndrome. J Child Neurol 25:1006–1008CrossRef
22.
Zurück zum Zitat Narula P, Gifford J, Steggall MA, Lloyd C, Van Mourik ID, Mckiernan PJ, Willshaw HE, Kelly D (2006) Visual loss and idiopathic intracranial hypertension in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 43:348–352PubMed Narula P, Gifford J, Steggall MA, Lloyd C, Van Mourik ID, Mckiernan PJ, Willshaw HE, Kelly D (2006) Visual loss and idiopathic intracranial hypertension in children with Alagille syndrome. J Pediatr Gastroenterol Nutr 43:348–352PubMed
23.
Zurück zum Zitat Polemikos M, Heissler HE, Hermann EJ, Krauss JK (2017) Idiopathic intracranial hypertension in monozygotic female twins: intracranial pressure dynamics and treatment outcome. World Neurosurg 101:814.e11–814.e14CrossRef Polemikos M, Heissler HE, Hermann EJ, Krauss JK (2017) Idiopathic intracranial hypertension in monozygotic female twins: intracranial pressure dynamics and treatment outcome. World Neurosurg 101:814.e11–814.e14CrossRef
24.
Zurück zum Zitat Sheldon CA, Kwon YJ, Liu GT, McCormack SE (2015) An integrated mechanism of pediatric pseudotumor cerebri syndrome: evidence of bioenergetic and hormonal regulation of cerebrospinal fluid dynamics. Pediatr Res 77:282–289CrossRef Sheldon CA, Kwon YJ, Liu GT, McCormack SE (2015) An integrated mechanism of pediatric pseudotumor cerebri syndrome: evidence of bioenergetic and hormonal regulation of cerebrospinal fluid dynamics. Pediatr Res 77:282–289CrossRef
25.
Zurück zum Zitat Sprung C, Schlosser HG, Lemcke J, Meier U, Messing-Jünger M, Trost HA, Weber F, Schul C, Rohde V, Ludwig HC, Höpfner J, Sepehrnia A, Mirzayan MJ, Krauss JK (2010) The adjustable proGAV shunt: a prospective safety and reliability multicenter study. Neurosurgery 66:465–474CrossRef Sprung C, Schlosser HG, Lemcke J, Meier U, Messing-Jünger M, Trost HA, Weber F, Schul C, Rohde V, Ludwig HC, Höpfner J, Sepehrnia A, Mirzayan MJ, Krauss JK (2010) The adjustable proGAV shunt: a prospective safety and reliability multicenter study. Neurosurgery 66:465–474CrossRef
26.
Zurück zum Zitat Thurtell MJ, Wall M (2013) Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol 15:1–12CrossRef Thurtell MJ, Wall M (2013) Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol 15:1–12CrossRef
27.
Zurück zum Zitat Tibussek D, Schneider DT, Vandemeulebroecke N, Turowski B, Messing-Juenger M, Willems PH, Mayatepek E, Distelmaier F (2010) Clinical spectrum of the pseudotumor cerebri complex in children. Childs Nerv Syst 26:313–321CrossRef Tibussek D, Schneider DT, Vandemeulebroecke N, Turowski B, Messing-Juenger M, Willems PH, Mayatepek E, Distelmaier F (2010) Clinical spectrum of the pseudotumor cerebri complex in children. Childs Nerv Syst 26:313–321CrossRef
28.
Zurück zum Zitat Tovia E, Reif S, Oren A, Mitelpunkt A, Fattal-Valevski A (2017) Treatment response in pediatric patients with pseudotumor cerebri syndrome. J Neuroophthalmol 37:393–397CrossRef Tovia E, Reif S, Oren A, Mitelpunkt A, Fattal-Valevski A (2017) Treatment response in pediatric patients with pseudotumor cerebri syndrome. J Neuroophthalmol 37:393–397CrossRef
29.
Zurück zum Zitat Wall M, George D (1991) Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 114:155–180CrossRef Wall M, George D (1991) Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 114:155–180CrossRef
30.
Zurück zum Zitat Warden KF, Alizai AM, Trobe JD, Hoff JT (2011) Short-term continuous intraparenchymal intracranial pressure monitoring in presumed idiopathic intracranial hypertension. J Neuroophthalmol 31:202–205CrossRef Warden KF, Alizai AM, Trobe JD, Hoff JT (2011) Short-term continuous intraparenchymal intracranial pressure monitoring in presumed idiopathic intracranial hypertension. J Neuroophthalmol 31:202–205CrossRef
Metadaten
Titel
Pseudotumor cerebri syndrome in a child with Alagille syndrome: intracranial pressure dynamics and treatment outcome after ventriculoperitoneal shunting
verfasst von
Manolis Polemikos
Elvis J. Hermann
Hans E. Heissler
Hans Hartmann
Joachim K. Krauss
Publikationsdatum
08.02.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Child's Nervous System / Ausgabe 9/2021
Print ISSN: 0256-7040
Elektronische ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-021-05043-9

Weitere Artikel der Ausgabe 9/2021

Child's Nervous System 9/2021 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Deutlich weniger Infektionen: Wundprotektoren schützen!

08.05.2024 Postoperative Wundinfektion Nachrichten

Der Einsatz von Wundprotektoren bei offenen Eingriffen am unteren Gastrointestinaltrakt schützt vor Infektionen im Op.-Gebiet – und dient darüber hinaus der besseren Sicht. Das bestätigt mit großer Robustheit eine randomisierte Studie im Fachblatt JAMA Surgery.

Chirurginnen und Chirurgen sind stark suizidgefährdet

07.05.2024 Suizid Nachrichten

Der belastende Arbeitsalltag wirkt sich negativ auf die psychische Gesundheit der Angehörigen ärztlicher Berufsgruppen aus. Chirurginnen und Chirurgen bilden da keine Ausnahme, im Gegenteil.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.